Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bioreactor scale up and protein product quality characterization of piggyBac transposon derived CHO pools

11 Feb 2017

Abstract excerpt

Chinese hamster ovary (CHO) cells remain the most popular host for the production of biopharmaceutical drugs, particularly monoclonal antibodies (mAbs), bispecific antibodies, and Fc-fusion proteins. Creating and characterizing the stable CHO clonally-derived cell lines (CDCLs) needed to manufacture these therapeutic proteins is a lengthy and laborious process. Therefore, CHO pools have increasingly been used to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Monoclonal and Polyclonal Antibodies Research
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28188692
DOI: 10.1002/btpr.2447

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bioreactor scale up and protein product quality characterization of piggyBac transposon derived CHO poolsPMID 28188692Read ↗

Generation of stable Chinese hamster ovary pools yielding antibody titers of up to 7.6 g/L using the piggyBac transposon systemSemantic proximity Read ↗

Rapid cGMP Manufacturing of COVID-19 monoclonal antibody using stable CHO cell poolsSemantic proximity Read ↗

Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable poolSemantic proximity Read ↗

Utilizing non-clonal CHO cell derived materials for preclinical studies of complex moleculesSemantic proximity Read ↗

Demonstration of a robust high cell density transient CHO platform yielding mAb titers of up to 2 g/L without medium exchangeSemantic proximity Read ↗

Advances in recombinant antibody manufacturingSemantic proximity Read ↗

Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-CloningSemantic proximity Read ↗

Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cellsSemantic proximity Read ↗

A CHO stable pool production platform for rapid clinical development of trimeric SARS‐CoV‐2 spike subunit vaccine antigensSemantic proximity Read ↗

Recombinant antibody-producing stable CHOK1 pool stability studySemantic proximity Read ↗

A comparative analysis of recombinant Fab and full‐length antibody production in Chinese hamster ovary cellsSemantic proximity Read ↗

Development of a high cell density transient CHO platform yielding mAb titers greater than 2 g/L in only 7 daysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.